COMP <GO>
RPRX vs JNJ // EV/EBITDA & P/E VALUATION
Royalty Pharma plc Class A Ordinary Shares (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: RPRX 5
— JNJ 8
▲ EV/EBITDA & P/E VALUATION LEADER: JNJ
LAST: $67.18 (+1.90%) • MKT CAP: $37.91B
valuation
27.8x
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
valuation
18.5x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RPRX VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RPRX | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 67.90% | -26.90 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 7.00% | 25.50% | -18.50 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 27.8x | 18.5x | +9.30 | JNJ | /valuation <GO> |
| Free Cash Flow Yield | 6.29% | 2.97% | +3.32 | RPRX | /fcf-yield <GO> |
| Operating Margin | 65.60% | 34.70% | +30.90 | RPRX | /operating-margins <GO> |
| Net Profit Margin | 32.40% | 28.50% | +3.90 | RPRX | /net-margins <GO> |
| Revenue Growth (YoY) | 5.10% | 6.00% | -0.90 | JNJ | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.90 | 5.59 | -2.69 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 8/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.70% | 7.20% | -0.50 | RPRX | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 76.7 | 60.4 | +16.38 | RPRX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.94 | 1.08 | -0.14 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 45.8x | 23.0x | +22.80 | JNJ | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $37.91B | $662.49B | -$624.58B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RPRX REV | JNJ REV | RPRX GROSS % | JNJ GROSS % | RPRX FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.38B | $94.19B | 44.0% | 67.9% | $2.38B | $19.70B |
| FY 2024 | $2.26B | $88.82B | 44.0% | 69.1% | $2.67B | $19.84B |
| FY 2023 | $2.35B | $85.16B | 44.0% | 44.0% | $2.88B | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RPRX // BETA 0.94
JNJ // BETA 1.08